Research in earlier phases or small trials include evaluation of GLP-1s for cystic fibrosis-related diabetes, polycystic ovarian syndrome (PCOS), chronic obstructive pulmonary disease (COPD), Prader-Willi syndrome (PWS), asthma, substance or alcohol use disorder, and as add-on to insulin for type 1 diabetes (T1DM)
Demodex mites People with rosacea often have more of these microscopic skin mites than those without the condition
Dysregulation of fat metabolism in mitochondria, possibly due to mitochondrial dysfunction, leads to a lack of fat oxidation, resulting in increased circulating fat levels and insulin resistance
For example, liraglutide, a GLP-1 receptor agonist, improved cognitive function in n = 19 patients with major depressive disorder (MDD) or bipolar disorder in a pilot randomised controlled trial (RCT) [16], whilst a systematic review and meta-analysis reported a pooled reduction in depressive symptoms with GLP-1 receptor agonists compared to other antidiabetic therapies [17]
Researchers also examined major adverse CV events in patient subgroups on the basis of major adverse CV event rates in the placebo group, the presence or absence of CVD, HbA1c level, trial duration, treatment dosing interval, structural homology to human GLP-1 or exendin-4, BMI, age and eGFR
Biochem Pharmacol 64:104956, PMID: 12213604 Poole LB, Karplus PA, Claiborne A (2004) Protein sulfenic acids in redox signaling